Articles From: Epiq Systems Names Karin-Joyce Tjon as Executive Vice President and Chief Financial Officer to EPR Properties Declares Monthly Dividend for Common Shareholders


KANSAS CITY, Kan., June 18, 2014 (GLOBE NEWSWIRE) -- Epiq Systems, Inc. (Nasdaq:EPIQ) , a leading provider of managed technology for the global legal profession, today announced the appointment of Karin-Joyce (KJ) Tjon as executive vice president and chief financial officer of the company effective July 1, 2014.
Sign-up for Epiq Systems Names Karin-Joyce Tjon as Executive Vice President and Chief Financial Officer investment picks
KANSAS CITY, Kan., July 15, 2014 (GLOBE NEWSWIRE) -- Epiq Systems, Inc. (Nasdaq:EPIQ) will report financial results for the second quarter ended June 30, 2014 after the close of the market on Thursday, July 31, 2014.
Sign-up for Epiq Systems Second Quarter 2014 Earnings Results to be Announced July 31, 2014 investment picks
NEW YORK, June 24, 2014 (GLOBE NEWSWIRE) -- Epiq Systems, Inc. (Nasdaq:EPIQ) , a leading provider of managed technology for the global legal profession, today announced that David Rohde, senior director of consulting services, has earned an Information Governance Professional (IGP) certification.
Sign-up for Epiq Systems Senior Director David Rohde Earns Information Governance Professional Certification investment picks
KANSAS CITY, Kan., July 29, 2014 (GLOBE NEWSWIRE) -- Epiq Systems, Inc. (Nasdaq:EPIQ) , a leading provider of managed technology for the global legal profession, today announced that Tom W.
Sign-up for Epiq Systems to Present at the Needham Interconnect Conference on August 5 investment picks
2014/8/7
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the company will present at the Wedbush Life Sciences Management Access Conference at 4:15 p.m. EDT, Tuesday, Aug.
Sign-up for EPIRUS to Present at Wedbush Life Sciences Management Access Conference investment picks
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has received final marketing and manufacturing approvals for its Remicade ® (infliximab) biosimilar, BOW015, from the Drug Controller General of India (DCGI). BOW015 is the first infliximab biosimilar approved in India.
Sign-up for EPIRUS’ Remicade® Biosimilar Receives Final Approvals in India investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0958668001&sourceType=1 http://www.ccnmatthews.com/logos/20080922-epistem200.jpg MANCHESTER, UNITED KINGDOM --
Sign-up for Epistem Plc: Announcement of Collaborative Funding Agreement With Global Health Investment Fund I, LLC investment picks
2014/7/21
EPIX, the premium entertainment network, announced today that boxing great and entrepreneur Oscar De La Hoya will be the next guest on Personal with Bill Rhoden, the network’s special interview series hosted by the award-winning sports journalist with The New York Times .
Sign-up for EPIX Captures Oscar De La Hoya as He Defines Himself, Life In and Out of the Ring investment picks
2014/7/7
Premium entertainment network EPIX announced today that To Russia With Love , an EPIX Original Documentary about two generations of Olympic LGBT athletes, will make its World Premiere Wednesday, October 22 at 8PM ET .
Sign-up for EPIX Explores LGBT Human Rights Journey as Seen Through Athletes’ Experience investment picks
2014/7/28
Premium entertainment network EPIX announced today that Forgotten Four: The Integration of Pro Football , an EPIX Original Documentary, will make its World Premiere on Tuesday, September 23, 2014, at 8PM ET .
Sign-up for EPIX Original Documentary Profiles Four African American Athletes Who Broke the Color Barrier investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Jason Rhodes, President and Chief Financial Officer, has resigned from the company, effective September 30, 2014.
Sign-up for Epizyme Announces Resignation of President and Chief Financial Officer Jason Rhodes investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced second quarter 2014 operating and financial results and reiterated 2014 guidance.
Sign-up for Epizyme Announces Second Quarter 2014 Financial Results and Provides Corporate Update investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development.
Sign-up for Epizyme Appoints Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D., as Vice President, Business Development investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, reported pre-clinical data and early clinical observations from an ongoing Phase 1 trial, being conducted in collaboration with Eisai, the Institut Gustave Roussy, and the Institut Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced solid tumors and B-cell lymphomas.
Sign-up for Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in five upcoming conferences in September: About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.
Sign-up for Epizyme to Present at Upcoming Conferences in September investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Wednesday, August 13, 2014 at 8:00 a.m. ET to report second quarter 2014 financial results and provide a corporate update.
Sign-up for Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014 investment picks
2014/9/10
HERNDON, Va., Sept.
Sign-up for ePlus Announces Changes to Board of Directors investment picks
2014/7/31
HERNDON, Va., July 31, 2014 (GLOBE NEWSWIRE) -- ePlus inc.
Sign-up for ePlus Announces First Quarter Fiscal Year 2015 Earnings Release Date and Conference Call investment picks
2014/6/16
HERNDON, Va., June 16, 2014 (GLOBE NEWSWIRE) -- ePlus inc.
Sign-up for ePlus Announces Stock Repurchase Program investment picks
2014/8/18
HERNDON, Va., Aug.
Sign-up for ePlus Expands Presence in California With Acquisition of Evolve Technology Group investment picks
2014/6/17
HERNDON, Va., June 17, 2014 (GLOBE NEWSWIRE) -- ePlus inc.
Sign-up for ePlus Named to CRN's 2014 Solution Provider 500 List investment picks
2014/8/6
Revenue increased 5% to $272.3 million, led by 6% growth in technology segment Gross margin expanded to 20.7% from 20.3%, driven by gross margin increase on products and services of 18.5% from 17.7% Earnings per diluted share of $1.25 includes gain on retirement of liability; excluding gain, non-GAAP earnings per diluted share was $1.14, up 17.5% from $0.97 per share HERNDON, Va., Aug.
Sign-up for ePlus Reports First Quarter Financial Results investment picks
2014/8/26
HERNDON, Va., Aug.
Sign-up for ePlus Selected by Surry County Public Schools for a Complete Collaboration Solution investment picks
2014/8/5
HERNDON, Va., Aug.
Sign-up for ePlus Technology Amends Credit Facility With GE Capital Commercial Distribution Finance investment picks
2014/8/4
HERNDON, Va., Aug.
Sign-up for ePlus to Present at the Canaccord Genuity 34th Annual Growth Conference investment picks
EPR Properties (NYSE:EPR) today announced that Standard & Poor’s Ratings Services (“S&P”) has raised the Company’s corporate credit rating to BB+ from BB.
Sign-up for EPR Properties Announces Ratings Upgrade from Standard & Poor’s Ratings Services investment picks
EPR Properties (NYSE: EPR) today announced that the Company’s President and CEO, David Brain, appeared as a featured guest on CNBC’s “Mad Money with Jim Cramer” Monday, July 28, 2014.
Sign-up for EPR Properties CEO David Brain Appears on CNBC’s “Mad Money with Jim Cramer” and Bloomberg’s “Market Makers” investment picks
EPR Properties (NYSE:EPR) today announced that its Board of Trustees has declared its monthly cash dividend to common shareholders.
Sign-up for EPR Properties Declares Monthly Dividend for Common Shareholders investment picks
EPR Properties (NYSE:EPR) today announced that its Board of Trustees has declared its monthly cash dividend to common shareholders.
Sign-up for EPR Properties Declares Monthly Dividend for Common Shareholders investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Epiq Systems Names Karin-Joyce Tjon as Executive Vice President and Chief Financial Officer to EPR Properties Declares Monthly Dividend for Common Shareholders
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices